cyclophosphamide + dexrazoxane + doxorubicin + trastuzumab

This is a combination regimen consisting of four agents: - **Cyclophosphamide** (an alkylating agent that crosslinks DNA, leading to cell death), - **Dexrazoxane** (a cardioprotective agent that chelates iron and reduces anthracycline-induced cardiotoxicity), - **Doxorubicin** (an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, causing cytotoxicity), and - **Trastuzumab** (a monoclonal antibody targeting the HER2/neu receptor, inhibiting proliferation of HER2-overexpressing tumor cells). This combination is not a standard named regimen but represents an intensification or modification of established regimens for HER2-positive breast cancer. Cyclophosphamide and doxorubicin are commonly used together as part of adjuvant or neoadjuvant chemotherapy for breast cancer. Trastuzumab is added in cases where tumors overexpress the HER2 protein to provide targeted therapy. Dexrazoxane may be included specifically to mitigate the risk of cardiac toxicity associated with concurrent use of doxorubicin and trastuzumab[1][6][7]. The primary indication for this combination would be early-stage or locally advanced HER2-positive breast cancer in patients at increased risk for cardiac complications.